A great number of researchers have found that immune checkpoints such as PD-1/PD-L1/PD-L2 and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) enable cancer cells to bypass human immunosurveillance, which therefore might be promising targets for immunotherapy. This evidence concerns the gene CTLA4 and cancer.